Synmosa Biopharma | Sustainability Performance
Develops and markets pharmaceutical products, focusing on respiratory, oncology, and specialty treatments, supported by research and development in biotechnology and healthcare solutions.
1970
Taiwan
501 - 1,000 employees
Pharmaceuticals
$100M - 500M in revenue
$25M - 100M in profitability
Sustainability Ranking & Industry Benchmark
#6911
Overall#102
in Taiwan#159
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$5.5BFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
4.7%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
7.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
4.4
▼ 1.5%
5.1
▼ 2.6%
5.5
▼ 1.4%
6.7
2025Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
31%
Independent Directors
4 out of 13 incl. management
Overall score
0
Environment
0
Social
0
Governance
0
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
